It has been reported that the majority of tumor‐specific CD8+ T cells are T cell factor‐1(TCF‐1)+ stem‐like T cells, and combining JX‐594 with anti‐PD‐1 improved the proliferation of these T cells and enhanced therapeutic effectiveness. The gene discussed is CD8A; the disease is neoplasm.